| HOME >> MEDICINE >> TECHNOLOGY |
2003-2007 (THOUSANDS) 81
TABLE 52 BREAST CANCER ESTIMATES IN ASIAN WOMEN, INCIDENCE, 2004-2008, AND
MORTALITY, 2003-2007 (PER 100,000) 81
TABLE 53 ESTIMATED BREAST CANCER INCIDENCE IN HISPANIC AND LATINA WOMEN,
2004–2008, AND MORTALITY, 2003–2007 (PER 100,000) 82
AGE AND BREAST CANCER 82
TABLE 54 BREAST CANCER RISK WITH AGE 83
BREAST CANCER AND RACE IN THE U.S. 83
TABLE 55 U.S. RATES, TRENDS AND CAUSE-SPECIFIC SURVIVAL FOR FEMALE BREAST
CANCER PATIENTS BY RACE OR ETHNICITY, 2001-2007 83
IN SITU BREAST CANCER 84
INVASIVE BREAST CANCER 84
INITIATIVE RANDOMIZED TRIAL RESULTS 85
INCIDENCE TRENDS BY RACE AND TUMOR SIZE 85
INCIDENCE AND MORTALITY TRENDS FOR MALE BREAST CANCER 85
FACTORS INFLUENCING BREAST CANCER SURVIVAL 86
TABLE 56 RELATIVE CANCER SURVIVAL IN WOMEN 86
OBESITY, PHYSICAL ACTIVITY AND DIET 86
TUMOR CHARACTERISTICS 86
AGE AT DIAGNOSIS 87
FAMILY HISTORY OF BREAST CANCER AND GENETIC PREDISPOSITION 87
HISTORICAL FACTS 88
CANADA 89
ESTIMATED NUMBER OF NEW CASES 89
TABLE 57 CANADA ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY
AGE, 2010 (THOUSANDS) 89
AUSTRALIA 90
TABLE 58 AUSTRALIA PROJECTED NEW CASES OF BREAST CANCER, 2011-2021 90
CHAPTER 7 BREAST CANCER DRUGS AND MARKET TRENDS 92
CLINICAL DIAGNOSIS AND MANAGEMENT 92
TABLE 59 APPROVED ONCOLOGY DRUGS, 2012 92
TABLE 60 APPROVED ONCOLOGY DRUGS, 2011 93
TABLE 61 APPROVED ONCOLOGY DRUGS, 2010 93
CANCER DRUGS AND MARKET TRENDS 94
INNOVATIONS IN THE BREAST CANCER THERAPEUTIC MARKET 94
BREAST CANCER AND DRUGS 94
EMERGING DIAGNOSTICS FOR CANCER DRUGS 95
TRIPLE NEGATIVE BREAST CANCER 96
POLY ADP RIBOSE POLYMERASE INHIBITORS 96
DRUGS APPROVED FOR BREA
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |